SYMBIOTEC PHARMALAB Q2 FY27 CONCALL: GUIDES 20% FY27 REVENUE GROWTH & 25% EBITDA GROWTH; TARGETS 30–40% CDMO EBITDA MARGINS, Q1 FY28 US ALT-PROTEIN COMMERCIALISATION & MID-FY28 INSULIN SALES